Metabolic dysfunction associated fatty liver disease (MAFLD) is diagnosed in a person with fatty liver based on imaging, noninvasive score, or histology, if the person is overweight or obese, has type 2 diabetes mellitus (T2DM), or has at least two metabolic
risk abnormalities.1
The local prevalence of MAFLD is estimated to be 20–40%.1
The severity of liver fibrosis is the single most important predictor of liver-related complications and mortality.1